Global Mycoplasma Genitalium Market Size, Share and Trends Analysis Report – Industry Overview and Forecast to 2032

Mycoplasma Genitalium Market Size

• The global Mycoplasma genitalium market size was valued at USD 150.00 million in 2024 and is expected to reach USD 210.07 million by 2032, at a CAGR of 4.30% during the forecast period
• The market growth is largely fueled by the increasing prevalence of Mycoplasma genitalium infections, advancements in diagnostic technologies, and heightened awareness among healthcare providers and the public
• Furthermore, rising demand for accurate, rapid, and reliable diagnostic solutions is establishing nucleic acid amplification tests (NAATs) and related diagnostic kits as the preferred detection method, especially in clinical and laboratory settings. These converging factors are accelerating the adoption of Mycoplasma genitalium diagnostics, thereby significantly boosting the industry’s growth

Mycoplasma Genitalium Market Analysis

• Mycoplasma genitalium, a sexually transmitted bacterium, is increasingly recognized as a critical pathogen in urogenital infections, making accurate diagnostics essential for effective treatment and management in both clinical and laboratory settings due to its association with persistent infections, antibiotic resistance, and reproductive health complications
• The escalating demand for Mycoplasma genitalium diagnostics is primarily fueled by the rising prevalence of infections worldwide, advancements in nucleic acid amplification tests (NAATs), and growing awareness among healthcare providers and patients regarding the importance of early detection and targeted treatment
• North America dominated the Mycoplasma genitalium diagnostics market with the largest revenue share of 31.51% in 2025, characterized by advanced healthcare infrastructure, high adoption of molecular diagnostics, and a strong presence of key industry players, with the U.S. experiencing substantial growth in testing and diagnosis, driven by innovations from both established diagnostic companies and emerging biotech firms
• Asia-Pacific is expected to be the fastest-growing region in the Mycoplasma genitalium diagnostics market during the forecast period due to increasing healthcare access, rising awareness of sexually transmitted infections, and expanding diagnostic capabilities in emerging economies
• Nucleic acid amplification tests (NAATs) dominated the Mycoplasma genitalium diagnostics market with a market share of 55.5% in 2024, driven by their high accuracy, rapid results, and suitability for integration into routine clinical testing workflows

Report Scope and Mycoplasma Genitalium Market Segmentation    

Mycoplasma Genitalium Market Trends

Advancements in Rapid and Multiplex Diagnostics

• A significant and accelerating trend in the global Mycoplasma genitalium diagnostics market is the increasing development of rapid and multiplex nucleic acid amplification tests (NAATs) that allow simultaneous detection of multiple sexually transmitted infections, improving efficiency and accuracy in clinical settings
  • For instance, the Aptima Mycoplasma genitalium assay integrates testing for M. genitalium alongside other STIs in a single workflow, enabling laboratories to deliver faster results with minimal sample handling
• Integration of advanced molecular techniques, including CRISPR-based detection and automated sample processing, allows improved sensitivity, specificity, and reduced turnaround time, facilitating early diagnosis and timely treatment
• The seamless combination of diagnostics with laboratory information management systems (LIMS) enables centralized reporting, tracking of infection trends, and automated alerts for unusual activity or resistance patterns
• This trend towards more precise, rapid, and interconnected diagnostic systems is reshaping clinical expectations for STI management. Consequently, companies such as Hologic are developing high-throughput and automated solutions with multiplex capabilities and AI-driven result interpretation
• The demand for rapid, accurate, and comprehensive Mycoplasma genitalium diagnostic solutions is growing rapidly across both clinical laboratories and hospital settings, as healthcare providers increasingly prioritize timely detection and treatment of infections

Mycoplasma Genitalium Market Dynamics

Driver

Increasing Prevalence and Awareness of Mycoplasma genitalium Infections

• The rising prevalence of Mycoplasma genitalium infections, coupled with growing awareness of antibiotic resistance and reproductive health implications, is a significant driver for the heightened demand for accurate diagnostic solutions
  • For instance, in June 2024, Roche introduced updates to its NAAT platform to enhance M. genitalium detection accuracy, aiming to support clinicians in early identification and appropriate treatment of infections
• As healthcare providers become more aware of persistent and resistant infections, advanced diagnostics allow timely intervention, reducing complications such as infertility, pelvic inflammatory disease, and treatment failures
• Furthermore, increasing inclusion of M. genitalium testing in standard STI screening panels is making diagnostic solutions an essential component of sexual health programs, especially in high-risk populations
• The convenience of automated, high-sensitivity testing, combined with the ability to generate rapid results and resistance profiles, is propelling adoption in both clinical laboratories and hospital settings. The trend toward comprehensive sexual health panels and increased patient awareness further contributes to market growth

Restraint/Challenge

High Cost of Advanced Diagnostics and Regulatory Hurdles

• Concerns surrounding the high cost of advanced molecular diagnostic kits and regulatory compliance pose significant challenges to broader market penetration, particularly in low- and middle-income regions
  • For instance, limited reimbursement policies and stringent approval processes can delay the introduction of new NAATs for M. genitalium, making adoption slower in resource-constrained healthcare systems
• Addressing these challenges requires cost-effective assay development, clear regulatory pathways, and demonstration of clinical utility to gain acceptance among laboratories and healthcare providers
• In addition, laboratory infrastructure limitations and the need for skilled personnel to operate complex molecular platforms can restrict deployment, especially in emerging markets
• While costs are gradually decreasing with technological advancements, the perceived premium for high-sensitivity and multiplex tests can still hinder widespread adoption
• Overcoming these barriers through training, subsidies, and simplified testing workflows will be vital for sustained market growth

Mycoplasma Genitalium Market Scope

The market is segmented on the basis of treatment, diagnosis, symptoms, route of administration, end-users, and distribution channels.

• By Treatment

On the basis of treatment, the Mycoplasma genitalium diagnostics market is segmented into antibiotics and others. The antibiotics segment dominated the market in 2024, accounting for the largest revenue share. Antibiotics such as azithromycin and moxifloxacin remain the first-line treatments for Mycoplasma genitalium infections. High prevalence of antibiotic-sensitive strains ensures widespread clinical adoption. Treatment guidelines from global health authorities reinforce reliance on antibiotics in hospitals and clinics. Continuous research into resistance management and updated dosing strategies sustains the segment’s growth. Moreover, patient familiarity and trust in antibiotics contribute to consistent market demand.

The others segment, including alternative and adjunct therapies, is expected to witness the fastest growth during the forecast period. Rising concerns about antibiotic resistance are driving the search for novel treatment options. Development of probiotics, supportive care therapies, and combination regimens contribute to market expansion. Personalized medicine approaches targeting patient-specific infections further boost adoption. Clinical trials for new therapeutic protocols increase potential market reach. Emerging markets with improving healthcare infrastructure are also key growth drivers.

• By Diagnosis

On the basis of diagnosis, the Mycoplasma genitalium diagnostics market is segmented into nucleic acid amplification test (NAAT) and others. The NAAT segment dominated the market in 2024 with a market share of 55.5% due to high sensitivity, specificity, and rapid turnaround time. NAAT is considered the gold standard for detecting Mycoplasma genitalium in clinical laboratories. Early detection enables resistance profiling and improved patient management. Routine STI screening panels increasingly integrate NAAT-based testing to enhance coverage. Government and private initiatives support wider adoption in hospitals and specialized clinics. The ability to detect asymptomatic infections strengthens demand across both developed and emerging markets.

The others segment, including culture-based methods and immunoassays, is expected to witness the fastest growth during forecast period. Simplified point-of-care testing and multiplex assays for multiple STIs are driving adoption. Lower infrastructure requirements make these methods suitable for clinics and community health centers. Affordability and ease of use attract patients in emerging markets. Mobile diagnostic technologies improve access in remote areas and rural populations. Increasing investment in decentralized healthcare infrastructure accelerates growth of this segment.

• By Symptoms

On the basis of symptoms, the Mycoplasma genitalium diagnostics market is segmented into watery discharge from penis, burning, stinging, or pain when urinating, pain during sex, discharge from vagina, bleeding between periods, bleeding after sex, pain in pelvic area, and others. The burning, stinging, or pain when urinating segment dominated in 2024. It is one of the most commonly reported symptoms that prompt early testing and diagnosis. Frequent clinical visits driven by this symptom increase diagnostic adoption. Healthcare providers prioritize patients presenting this symptom for NAAT testing. Awareness campaigns emphasize testing based on this symptom to prevent complications. Its prevalence ensures consistent demand for treatment across hospitals and clinics globally.

The others segment, comprising atypical or less common symptoms, is expected to witness the fastest growth during forecast period. Recognition of uncommon presentations drives screening in previously underdiagnosed populations. Telehealth services and patient education facilitate early symptom reporting. Inclusion in comprehensive STI panels increases detection rates in asymptomatic patients. Community awareness programs encourage identification of atypical infections. Emerging markets with growing sexual health initiatives further accelerate segment growth.

• By Route of Administration

On the basis of route of administration, the Mycoplasma genitalium diagnostics market is segmented into oral, intravenous, and others. The oral segment dominated in 2024 due to convenience, high patient compliance, and outpatient treatment capability. Oral antibiotics reduce hospital stays and associated treatment costs. Widespread clinical familiarity enhances adoption across hospitals and clinics. Global treatment guidelines recommend oral therapy as first-line management. Effective eradication rates sustain continued usage and repeat prescriptions. Its preference in both developed and emerging markets reinforces market dominance.

The others segment, including topical or localized therapies, is expected to witness the fastest growth during forecast period. Targeted drug delivery minimizes systemic side effects and improves patient comfort. Combination therapies for resistant infections further increase adoption. Clinical trials exploring alternative administration methods expand market potential. Rising patient demand for novel therapies contributes to segment growth. Adoption in emerging markets with limited hospital infrastructure supports rapid uptake.

• By End-Users

On the basis of end-users, the Mycoplasma genitalium diagnostics market is segmented into clinics, hospitals, and others. The hospital segment dominated in 2024 due to advanced diagnostic infrastructure and higher patient volumes. Hospitals integrate NAAT-based testing into routine STI screening programs. They provide follow-up care, resistance monitoring, and treatment compliance support. Awareness campaigns and screening initiatives further drive hospital-based testing. Hospitals serve as primary points of care for symptomatic patients. Established clinical workflows and higher treatment adherence ensure sustained revenue and growth.

The clinics segment is expected to witness the fastest growth during the forecast period. Outpatient testing and rapid diagnostic solutions are driving higher adoption in clinics. Growing sexual health awareness encourages patients to seek early detection through clinic visits. Telehealth services and community-based initiatives improve accessibility for patients. Point-of-care diagnostic kits enhance testing convenience and reduce turnaround time. Expansion of healthcare infrastructure in emerging markets further accelerates clinic-based growth.

• By Distribution Channel

On the basis of distribution channel, the Mycoplasma genitalium diagnostics market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment dominated in 2024 due to integration with diagnostics and prescribed antibiotics. Immediate patient access and reliable supply reinforce hospital pharmacy dominance. High patient volumes and clinical workflows ensure consistent revenue. Hospitals are the primary point of care for symptomatic patients requiring rapid treatment. Trusted distribution networks and clinician recommendations sustain adoption. Coordination with hospital testing protocols ensures effective dispensing and patient compliance.

The online pharmacy segment is expected to witness the fastest growth during forecast period. Digital adoption and telehealth consultations drive convenient access to diagnostics and medications. Home delivery improves accessibility for patients in remote areas. Regulatory support for online pharmacies accelerates adoption and compliance. Online platforms facilitate prescription management, rapid shipment, and privacy for patients. Consumer preference for contactless healthcare solutions further fuels rapid growth and market penetration.

Mycoplasma Genitalium Market Regional Analysis

• North America dominated the Mycoplasma genitalium diagnostics market with the largest revenue share of 31.51% in 2025, characterized by advanced healthcare infrastructure, high adoption of molecular diagnostics, and a strong presence of key industry players
• Healthcare providers and laboratories in the region highly value the accuracy, rapid results, and resistance profiling offered by nucleic acid amplification tests (NAATs) and other modern diagnostic methods
• This strong adoption is further supported by well-established healthcare infrastructure, high awareness of sexual health, and the presence of key industry players, establishing North America as a leading market for Mycoplasma genitalium testing and treatment

U.S. Mycoplasma Genitalium Market Insight

The U.S. Mycoplasma genitalium diagnostics market captured the largest revenue share of 82% in North America in 2025, fueled by rising awareness of sexually transmitted infections and the widespread adoption of advanced diagnostic technologies. Healthcare providers increasingly prioritize accurate detection, rapid results, and resistance profiling through nucleic acid amplification tests (NAATs). Growing initiatives for sexual health screening and preventive care further drive market demand. The availability of cutting-edge laboratory infrastructure supports timely diagnosis and treatment. In addition, public health campaigns and telehealth services enhance accessibility to testing. Rising antibiotic resistance concerns are also promoting the adoption of targeted diagnostic solutions.

Europe Mycoplasma Genitalium Market Insight

The Europe Mycoplasma genitalium diagnostics market is projected to expand at a substantial CAGR throughout the forecast period, driven by increasing awareness of sexually transmitted infections and the growing need for rapid and accurate diagnostic solutions. Government initiatives promoting sexual health and preventive screening programs are encouraging market adoption. Urbanization, higher disposable incomes, and growing healthcare access foster demand in both hospitals and clinics. The market is witnessing growth across residential clinics, hospitals, and specialized laboratories. Advanced molecular diagnostic technologies and awareness campaigns are key adoption drivers. The region also emphasizes compliance with healthcare regulations, supporting the integration of modern diagnostic solutions.

U.K. Mycoplasma Genitalium Market Insight

The U.K. Mycoplasma genitalium diagnostics market is anticipated to grow at a noteworthy CAGR during the forecast period, driven by increasing sexual health awareness and rising infection rates. Concerns regarding reproductive health and antibiotic resistance are encouraging testing and early diagnosis. The adoption of rapid NAAT-based diagnostics in clinics and hospitals is accelerating market expansion. Telehealth services and community-based health initiatives are improving patient access. The U.K.’s robust healthcare infrastructure and supportive regulatory environment further facilitate market growth. Integration of diagnostics with comprehensive STI panels enhances detection and treatment efficiency.

Germany Mycoplasma Genitalium Market Insight

The Germany Mycoplasma genitalium diagnostics market is expected to expand at a considerable CAGR during the forecast period, fueled by increasing awareness of sexually transmitted infections and advanced healthcare infrastructure. Hospitals and clinics are adopting NAAT-based diagnostics for accurate detection and resistance profiling. Growing emphasis on reproductive health and preventive care is encouraging early testing. Germany’s focus on innovation in medical technology supports the adoption of automated diagnostic platforms. Integration with laboratory information systems ensures efficient patient management. The preference for reliable, high-accuracy testing solutions aligns with local healthcare standards and consumer expectations.

Asia-Pacific Mycoplasma Genitalium Market Insight

The Asia-Pacific Mycoplasma genitalium diagnostics market is poised to grow at the fastest CAGR during the forecast period, driven by rising awareness of sexually transmitted infections, expanding healthcare access, and increasing laboratory infrastructure in countries such as China, Japan, and India. Growing urbanization and disposable incomes are supporting higher adoption of modern diagnostics. Government initiatives promoting sexual health screening and preventive programs further boost market growth. Increasing demand for point-of-care NAAT kits improves accessibility in clinics and hospitals. The region’s emergence as a hub for diagnostic kit manufacturing reduces costs and enhances availability. Rising sexual health education and public awareness campaigns further accelerate adoption.

Japan Mycoplasma Genitalium Market Insight

The Japan Mycoplasma genitalium diagnostics market is gaining momentum due to high public awareness, well-developed healthcare infrastructure, and the adoption of advanced diagnostic technologies. NAAT-based testing is increasingly preferred for accurate detection and resistance profiling. Growing emphasis on reproductive health and preventive care encourages early diagnosis. Integration of diagnostics with hospital information systems enhances patient management and reporting. Telehealth services support accessibility in both urban and rural areas. The aging population further drives demand for convenient and reliable diagnostic solutions in hospitals and clinics.

India Mycoplasma Genitalium Market Insight

The India Mycoplasma genitalium diagnostics market accounted for the largest market revenue share in Asia-Pacific in 2024, attributed to increasing sexual health awareness, expanding healthcare infrastructure, and rising laboratory capabilities. Rapid urbanization and growing middle-class population drive the adoption of modern diagnostic technologies. Government initiatives promoting STI screening and preventive care enhance market growth. Affordable diagnostic kits and local manufacturing support wider accessibility. Clinics, hospitals, and community health centers are increasingly adopting NAAT-based testing. Public awareness campaigns and telehealth services further contribute to the expansion of the diagnostics market in India.

Mycoplasma Genitalium Market Share

The Mycoplasma Genitalium industry is primarily led by well-established companies, including:

• Quest Diagnostics Incorporated (U.S.)
• Labcorp (U.S.)
• Hologic, Inc. (U.S.)
• SpeeDx Pty Ltd (Australia)
• ATCC (U.S.)
• ELITechGroup (U.S.)
• Incyte Diagnostics, Inc. (U.S.)
• myLAB Box, Inc. (U.S.)
• Wisp Health, Inc. (U.S.)
• HealthLabs.com (U.S.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• BIOMÉRIEUX (France)
• Thermo Fisher Scientific Inc. (U.S.)
• Cepheid, Inc. (U.S.)
• Abbott (U.S.)
• BD (U.S.)
• PerkinElmer (U.S.)
• QIAGEN (Germany)
• Bio-Rad Laboratories, Inc. (U.S.)
• GenMark Diagnostics, Inc. (U.S.)

What are the Recent Developments in Global Mycoplasma Genitalium Market?

• In July 2025, the British Association for Sexual Health and HIV released updated national guidelines for managing Mycoplasma genitalium infections. The guidelines provide comprehensive recommendations on diagnosis, treatment, and prevention, reflecting the latest clinical evidence
• In June 2025, Wisp, a telehealth company, expanded its services to include at-home testing for Mycoplasma genitalium, alongside other STIs such as Chlamydia and Gonorrhea. This move aims to enhance accessibility to sexual health diagnostics, particularly for individuals seeking privacy and convenience
• In April 2025, Labcorp announced the nationwide rollout of FDA-approved self-collection solutions for HPV and STI testing, including Mycoplasma genitalium. Available at over 2,200 Patient Service Centers and participating physician offices across the U.S., this initiative aims to enhance accessibility and convenience for patients seeking STI testing
• In March 2025, the CDC published a study identifying a dual-resistant Mycoplasma genitalium clone prevalent in France. The research highlights the increasing challenge of antibiotic resistance in STIs and underscores the need for enhanced surveillance and updated treatment protocols
• In June 2024, SpeeDx launched the ResistancePlus MG FleXible test, a molecular diagnostic tool designed to detect Mycoplasma genitalium and identify macrolide resistance directly from patient samples. This development addresses the growing concern of antibiotic resistance in STIs

SKU-67129